Genetic Features and Immunoprofile of Sporadic Well-Differentiated Neuroendocrine Tumors of Gastric Abstract #1840

Introduction: Well-differentiated Type III gastric neuroendocrine tumors (gNET III) are histologically distinct subset that have a unique pathogenesis and clinical course.
Aim(s): To further evaluate the genetic, pathological, and clinical features of gNET III.
Materials and methods: We analyzed the expression of Ki67, SSTR2/5 in gNET III in relation to alterations in the PI3K-Akt pathway, TP53 status (p53/Rb immunohistochemistry) and ALT were detected (ATRX, DAXX). Fisher’s exact test and X2 was performed.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Prof. Yuan Ji
Keywords: genetic, wdnet.

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1775 Potential Therapeutic Targets for Gastric Poorly Differentiated Neuroendocrine Carcinoma
Introduction: Gastric poorly differentiated neuroendocrine carcinoma (G-PDNEC) is rare and aggressive. Patients often present with distant metastases at initial diagnosis.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PROF. Yuan Ji
Authors: Ji Y, Xie Y, Chen K, Zeng H, ...
#1441 Epidemiology and Treatment Strategy of Neuroendocrine Neoplasms in North China
Introduction: Few studies had focus on the epidemiology of neuroendocrine neoplasms (NENs) , a rare disease, in China.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Qian-Nan Wang
Authors: Wang Q N, Jia R, Chen Y, Zhao C H, ...
#1678 Multicenter Retrospective Analysis of Clinical and Pathological Features of Gastroesophageal Junction Neuroendocrine Neoplasm(GEJ-NEN)
Introduction: GEJ-NEN is mostly poorly differentiated NEC with poor prognosis.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Panpan Zhang
Authors: Zhang P, Lu M, Shen L, Wang W, ...
#1697 An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967)
Introduction: Patients (pts) with advanced neuroendocrine tumors (NETs) who have failed sunitinib or everolimus have limited treatment options. Sulfatinib, a novel kinase inhibitor targeting tumor angiogenesis and immune evasion, has shown encouraging anti-tumor activity in patients with advanced NETs in a phase I study.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Jian Ming Xu
Authors: Xu J, Li J, Bai C M, Xu N, ...
Keywords: sulfatinib, net, orr, pfs
#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell